for Journals by Title or ISSN
for Articles by Keywords

Publisher: Horizon Research Publishing   (Total: 54 journals)   [Sort by number of followers]

Showing 1 - 54 of 54 Journals sorted alphabetically
Advances in Diabetes and Metabolism     Open Access   (Followers: 16)
Advances in Economics and Business     Open Access   (Followers: 11)
Advances in Energy and Power     Open Access   (Followers: 12)
Advances in Pharmacology and Pharmacy     Open Access   (Followers: 7)
Advances in Signal Processing     Open Access   (Followers: 11)
Advances in Zoology and Botany     Open Access  
Bioengineering and Bioscience     Open Access   (Followers: 1)
Cancer and Oncology Research     Open Access   (Followers: 8)
Chemical and Materials Engineering     Open Access   (Followers: 13)
Civil Engineering and Architecture     Open Access   (Followers: 18)
Computational Research     Open Access   (Followers: 1)
Computer Science and Information Technology     Open Access   (Followers: 13)
Energy and Environmental Engineering     Open Access   (Followers: 7)
Environment and Ecology Research     Open Access   (Followers: 7)
Food Science and Technology     Open Access   (Followers: 3, SJR: 0.11, h-index: 6)
Immunology and Infectious Diseases     Open Access   (Followers: 9)
Intl. J. of Biochemistry and Biophysics     Open Access   (Followers: 1)
Intl. J. of Cardiovascular and Cerebrovascular Disease     Open Access   (Followers: 2)
Intl. J. of Neuroscience and Behavioral Science     Open Access   (Followers: 1)
Linguistics and Literature Studies     Open Access   (Followers: 4)
Manufacturing Science and Technology     Open Access   (Followers: 2)
Mathematics and Statistics     Open Access   (Followers: 5)
Nanoscience and Nanoengineering     Open Access   (Followers: 1)
Natural Resources and Conservation     Open Access   (Followers: 6)
Nursing and Health     Open Access   (Followers: 3)
Open J. of Dentistry and Oral Medicine     Open Access  
Sociology and Anthropology     Open Access   (Followers: 5)
Sport and Art     Open Access   (Followers: 1)
Universal J. of Accounting and Finance     Open Access   (Followers: 2)
Universal J. of Agricultural Research     Open Access   (Followers: 1)
Universal J. of Applied Mathematics     Open Access   (Followers: 5)
Universal J. of Applied Science     Open Access   (Followers: 2)
Universal J. of Biomedical Engineering     Open Access  
Universal J. of Chemistry     Open Access  
Universal J. of Clinical Medicine     Open Access  
Universal J. of Communications and Network     Open Access  
Universal J. of Computational Mathematics     Open Access   (Followers: 4)
Universal J. of Control and Automation     Open Access   (Followers: 3)
Universal J. of Educational Research     Open Access  
Universal J. of Electrical and Electronic Engineering     Open Access   (Followers: 6)
Universal J. of Engineering Science     Open Access   (Followers: 1)
Universal J. of Food and Nutrition Science     Open Access   (Followers: 5)
Universal J. of Geoscience     Open Access   (Followers: 3)
Universal J. of Industrial and Business Management     Open Access   (Followers: 1)
Universal J. of Management     Open Access  
Universal J. of Materials Science     Open Access   (Followers: 3)
Universal J. of Mechanical Engineering     Open Access   (Followers: 10)
Universal J. of Medical Science     Open Access  
Universal J. of Microbiology Research     Open Access  
Universal J. of Physics and Application     Open Access   (Followers: 2)
Universal J. of Plant Science     Open Access  
Universal J. of Psychology     Open Access   (Followers: 2)
Universal J. of Public Health     Open Access   (Followers: 2)
World J. of Computer Application and Technology     Open Access   (Followers: 3)
Journal Cover Cancer and Oncology Research
  [8 followers]  Follow
  This is an Open Access Journal Open Access journal
   ISSN (Print) 2331-6128 - ISSN (Online) 2331-6136
   Published by Horizon Research Publishing Homepage  [54 journals]
  • Window-of-opportunity Study Testing the Antiproliferative Effect of
           Atorvastatin in Egyptian Patients with Operable Breast Cancer

    • Abstract: Publication date:  Nov 2017
      Source:Cancer and Oncology Research  Volume  5  Number  4  Bader A. Abdelmaksoud   Mohamed I. Abdelhamid   Salah Abd Elaal   and Hayam E. Rashed   Background and purpose: Cholesterol-lowering drugs (statins) appear to have pleiotropic effects independent of cholesterol level. The aim of this study was to assess the effect of pre-operative therapy with a statin (atorvastatin) on tumor proliferation in patients with newly diagnosed breast cancer. Methods: Thirty cases with histologically proven breast cancer were subjected to treatment by atorvastatin 80 mg /day for at least 14 days before the final surgical procedure (MRM or BCS). Immunohistochemical expression of Ki-67 staining of breast tumor cells was evaluated to assess tumor proliferation in biopsy tissues before treatment with atorvastatin then in final surgical tissues specimens. Results: The median age of the patients was 49.5 ranging from 29 to 61 years. The vast majority of the patients had invasive duct carcinoma (IDC) and was positive for estrogen and progesterone receptors. The mean pretreatment Ki67 index was high in the majority of patients and was significantly associated with both tumor grade and estrogen receptor status (P = 0.001 and P= 0.003, respectively). The Ki67 index had decreased in the post-treatment samples after final surgery in 19 cases, increased in 8 cases and unchanged in 3 cases compared to the pre-treatment specimens. Tumor grade is a significant predictor of treatment response (p=0,05). Conclusion: Atorvastatin decreased tumor proliferation in breast cancer especially in high grade tumors and its role should be considered in the future studies.
      PubDate: Nov 2017
  • Targeting the Seven Cancer Hallmarks by Modulation of Oxidative
           Stress-induced Inflammation and Immune Activation: A Radical Therapeutic

    • Abstract: Publication date:  Jun 2017
      Source:Cancer and Oncology Research  Volume  5  Number  2  Mburu Samuel   Cancer killed approximately 8.8 million people in 2015 globally. Furthermore, more than 27,000 Kenyans die annually from cancers, making it number three killers after infectious and cardiovascular diseases. The current therapeutic strategies are limited in their approach, therefore not effective enough to achieve complete remission. A radical multifactorial approach targeting early events in carcinogenesis is required. The purpose of this descriptive study was to review existing studies for knowledge, research gaps in the role of oxidative stress, inflammation, immune activation in carcinogenesis and cancer hallmarks, to stimulate new research ideas which can accelerate future therapeutic target discoveries. PubMed, ScienceDirect and Google scholar databases were searched using the keywords: cancer, oxidative stress, inflammation, immune activation, carcinogenesis and cancer hallmarks. Although widely recognized, little research on oxidative stress, inflammation, immune activation, as cancer therapeutic targets has been done. In addition, studies relating oxidative stress, inflammation, immune activation with cancer hallmarks, especially replicative immortality, immune evasion, and evading growth suppression are inadequate. To highlight this, out of a total of 8,680,095 hits, only 139,694 hits related to oxidative stress, inflammation, immune activation as therapeutic targets making this area a fertile ground for future research. Similarly, out of 271, 194 hits, only 4,595 were relating oxidative stress, inflammation and immune activation with replicative immortality as a cancer hallmark. Subsequently, after pearling, 129 articles that were directly relevant to the study were selected. After critical appraisal, identified studies were analyzed, results compared and presented in form of summary tables. Despite enough documented evidence of the essential role oxidative stress, inflammation, immune activation, plays in carcinogenesis, specific role in induction of cancer hallmarks, whether causal or consequence is not clear. An understanding of the early changes that marks initiation, maintenance and progression of cancer will accelerate development of future novel therapeutic targets and prevention strategies. This will have a direct impact on prevention, early diagnosis, management and treatment of cancers in Africa, thereby helping in attainment of United Nations sustainable development goal (SDG) number three.
      PubDate: Jun 2017
  • Similarities in Asymptomatic HIV Infection and Cancer: A Common 'Driver'

    • Abstract: Publication date:  Jun 2017
      Source:Cancer and Oncology Research  Volume  5  Number  2  Mburu Samuel   Cancer and Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) are associated with chronic oxidative stress, inflammation and immune activation either as a consequence or a cause. Despite well documented characteristic similarities in the two diseases, this has not been exploited for better understanding of carcinogenesis. The purpose of this descriptive study was to review existing studies for knowledge, research gaps in the role of oxidative stress, inflammation, immune activation in cancer and asymptomatic HIV infection; identify similarities, differences to stimulate new research ideas which can accelerate future therapeutic target discoveries. PubMed, ScienceDirect and Google scholar databases were searched using the keywords: oxidative stress, inflammation, immune activation, cancer and asymptomatic HIV infection. Little research has been done on immune evasion, tolerance and oxidative stress-induced inflammation and immune activation as therapeutic targets in both diseases. Senescence and the role of respiratory burst in HIV infection have not been exhaustively studied. Out of a total of 15,788,387 hits, 15, 284,572 hits related to similarities with only 503, 815 relating to the differences between the two diseases. Consequently and after pearling, 89 articles that were directly relevant to the study were selected. After critical appraisal, the identified studies were analyzed, results compared and presented in form of summary tables. Results indicated that chronic oxidative stress, inflammation and immune activation were common drivers of progression in the two diseases. Therefore, better understanding of these drivers might provide new mechanistic insights in carcinogenesis and provide future novel therapeutic targets. This will support the United Nations sustainable development goal (SDG) number 3 on ensuring health lives and promoting well-being for all at all ages.
      PubDate: Jun 2017
  • The Measurement of Delay in Diagnosis and Treatment among Moroccan Women
           with Cervical Cancer

    • Abstract: Publication date:  Feb 2017
      Source:Cancer and Oncology Research  Volume  5  Number  1  Fatima Ouasmani   Zaki Hanchi   Bouchra Haddou Rahou   Rachid Bekkali   Bouchra Benazzouz   and Abdelhalem Mesfioui   In Morocco, most of the cervical cancer patients have been reported diagnosed at advanced stage indicating delay in seeking diagnosis and treatment. The main purpose of this investigation was to measure the delay from the first symptom to treatment among Moroccan women with cervical cancer. Methods: We conducted a cross-sectional study at the National Institute of Oncology Sidi Mohammed Ben Abdellah in Rabat, Morocco. A consecutive series of patients with locally advanced cervical cancer or metastasic [stage II-IV] were recruited. We calculated delay by using two events dates of two periods in patient's pathway. Multivariate binary logistic regression analysis was performed to measure the association between all categories of delay and magnitude of total delay. Results: Four hundred and one patients were reached in this study. The median total delay was 183 days, the median patient delay was 120 days, the median diagnosis delay was 110 days, and the median Treatment delay was 57 days. Bivariate analysis showed that patients who did not have respectively patient and diagnosis delay were less likely to have total delay (p
      PubDate: Feb 2017
  • Self-reported Use of Complementary and Alternative Medicine among Moroccan
           Women with Breast Cancer

    • Abstract: Publication date:  Feb 2017
      Source:Cancer and Oncology Research  Volume  5  Number  1  Bouchra Haddou Rahou   Karima El Rhazi   Zaki Hanchi   Fatima Ouasmani   Bouchra Benazzouz   and Abdelhalem Mesfioui   The objective of this study was to assess the prevalence, types, sociodemographic and clinical-related factors of complementary and alternative medicine use among Moroccan women with breast cancer. A cross-sectional study was carried out at the National Institute of Oncology in Rabat. 400 patients with breast cancer were recruited for face-to-face interviews. Data were collected using a questionnaire addressing personal/medical characteristics and the use of CAM therapies. 88.5% of women used at least one CAM therapy, 73.2% of them reported began to use CAM at the onset of breast cancer symptoms. Type of CAM commonly used were prayers, listening and/or reading the Koran and use of naturel products like honey or fenugreek. High education level was independent factors related to CAM use. Interventions should be focused on open communication and further researches are needed to explore the safety and the outcome of CAM use.
      PubDate: Feb 2017
  • Towards a Personalized Cancer Gene Therapy: A Case of Clear Cell Renal
           Cell Carcinoma

    • Abstract: Publication date:  Aug 2017
      Source:Cancer and Oncology Research  Volume  5  Number  3  Dumitru Andrei Iacobas   and Sanda Iacobas   An ideal cancer gene therapy would selectively destroy the cancer nodules with negligible effects on the surrounding not yet compromised tissue. This would be possible if the targeted genes are in command positions in the cancer but not in the normal cells. Logic dictates that, while being strongly protected by the homeostatic mechanisms, expression of a commander gene governs most major functional pathways by regulating the expression of numerous other genes. Owing to the cancer dependence on race, sex, age, genetic heritage, medical history, environmental and lifestyle associated risk factors each patient has most likely a distinct, dynamic and never repeatable set of commander genes. Here we introduce the "gene commanding height" as a measure of gene rank in the cell hierarchy and test our procedure on a surgically removed metastatic clear cell renal cell carcinoma. Results indicate that each histopathologically distinct region has a unique set of commander genes and that cancer cell commanders are in low positions in normal cells. We believe that the genomic oncology should identify the cancer cell commander genes of the individual patient instead of testing for the biomarkers selected from most frequently altered genes in large populations.
      PubDate: Aug 2017
  • Presumably Common Trigger Mechanism of Action of Diametrically Different
           Carcinogens on Target Cells

    • Abstract: Publication date:  Sep 2013
      Source:Cancer and Oncology Research  Volume  1  Number  2  G.K. Gogichadze T.G. Gogichadze and G.K. Kamkamidze A large number of carcinogens and the wide spectrum of their actions may indicate their ability to trigger a common, general mechanism inside the normal biological program of somatic cells, which can lead to the development of the carcinogenic transformation of the normal cell. Numerous carcinogenic substances and factors of different natures probably can signify that these carcinogens must start up some common mechanism of normal cells transition into transformed states. Influence of physical, chemical, and biological carcinogenic agents on cells probably are adequate. By our opinion the common mechanism of action of diametrically different carcinogens on target-cells is the destruction of the plasmatic membrane. After influence of different carcinogens, cells’ fusion originates as a result of cytoplasmic membranes perforations (or modifications), i.e. formation in plasma membranes pores, what induces alteration of summary superficial charge of cells’ surface. Because of these, cells acquire ability to approach each other (adhesion), what in many cases may be a premise for fusion process. Thus, the initial target of carcinogenic agents is cells’ plasma membrane, but not the genetic apparatus of cells.
      PubDate: Sep 2013
  • Evaluation of Community-Based Projects to Reduce Cancer Disparities among
           Underrepresented Groups and Participants Satisfaction in Health
           Disparities Projects

    • Abstract: Publication date:  Sep 2013
      Source:Cancer and Oncology Research  Volume  1  Number  2  Saleh M.M. Rahman Jay Brown Selina Rahman Helene Vilme and Monica Hayes Cancer is the second leading cause of death in the United States. The objectives of this study were to evaluate cancer prevention programs and participants satisfaction in 51 disparities projects in Florida. This three-phase evaluation included evaluability assessment, process, immediate outcome and impact evaluation using qualitative assessment, case study, document analysis, face-to-face interviews, and survey. In 2006-2007, a total of 3,165, and in 2008-2009, a total of 1,632 individuals participated in the programs respectively. In breast and cervical cancer prevention programs, change of proportion of African-American and Haitian recruitment significantly increased from 2006-2008 to 2007-2009 (-11.3 to 3.4). Among other services, all means of outreach such as mobile vans, faith-based activities, health fairs, and small-group education sessions also increased by 5.3%, 7.9%, 5.5%, and 9.4% respectively. In participants' satisfaction the majority of respondents (N=231) were 35-54 years old (46.7%), non-Hispanic Black (81.7%), female (70.3%), high school and some college educated (58.8%), and with income less than $25,000 (65.5%). The majority of the participants were very satisfied with the program staff’s training, cultural sensitivity, language skills, resources, education materials, referral system, and changing behavior (mean score: 4.5-4.7) and with the overall project and the project’s role in improving their quality of life.
      PubDate: Sep 2013
  • Multiple Metachronous Granular Cell Tumors of the Gastrointestinal Tract
           within a Single Patient: a Case Report and Review of the Literature

    • Abstract: Publication date:  Sep 2013
      Source:Cancer and Oncology Research  Volume  1  Number  2  Jeffrey M. Sutton MD Jonathan Tobias MD and Ian M. Paquette MD Introduction: Granular cell tumors are a rare form of soft tissue tumor often arising from the skin and subcutaneous tissues of the head, trunk, or extremities, although they rarely may arise within the colon or gastrointestinal tract. Case Report: We present a case of a 28 year-old female who initially presented with recurrent granular cell tumors of the stomach treated with endoscopic polypectomy. She eventually developed a metachronous lesion within the ascending colon and underwent a segmental colectomy. We present her treatment course, pathological findings, and review of the literature of this unique condition.
      PubDate: Sep 2013
  • Cancer as a Continuum: a Literature Review and a Biological Interpretation

    • Abstract: Publication date:  Sep 2013
      Source:Cancer and Oncology Research  Volume  1  Number  2  Oddone E Crosignani P and Modonesi  C Basic research shows that the genetic control of development cannot fully explain the phenotypic plasticity of humans and other metazoans. This challenges some tenets of the conventional paradigm of life sciences based on DNA, restoring a role of the environment in biological processes like the regulation of development, cell differentiation and disease. The environment — in a broad sense — affects biological phenotypes throughout the entire lifespan and can induce cancer, its progression and recurrence as well as its reversal. This is very important in cancer epidemiology as it implies that environmental exposures can be considered both as risk (or protective) and prognostic factors. This review integrates information from epidemiologic and biological research. We studied the impact of hazardous and protective exposures, lifestyles, and diet on the survival of patients who had been diagnosed with cancer. We selected studies from two digital databases, using a few combinations of key terms, namely overall survival, cancer-specific survival, recurrence and quality of life (QoL). Survival and/or recurrence were expressed as hazard or risk ratios, as second cancer diagnosis and as indicators of QoL such as performance status. We found 53 articles indicating that risk and protective factors can also influence prognosis after cancer diagnosis. Cigarette smoking and, among protective factors, diet and physical activity are the exposures most frequently investigated after a diagnosis of cancer.
      PubDate: Sep 2013
  • Prevalence and Impacts of Upper Limb Morbidity after Treatment for Breast
           Cancer: A Cross-Sectional Study of Lymphedema and Function

    • Abstract: Publication date:  Sep 2013
      Source:Cancer and Oncology Research  Volume  1  Number  2  Catherine Bulley Fiona Coutts Christine Blyth Wilma Jack Mr Udi Chetty Matthew Barber and Chee Wee Tan A cross-sectional study screened lymphedema, impaired upper limb function (ULF) and quality of life (QOL) in women post-breast cancer. Women attending review appointments who had completed surgery, chemotherapy and radiotherapy, were without recurrence, and could complete questionnaires in English were invited. Medical records were reviewed and questionnaires completed: the Morbidity Screening Tool (MST), Disability of the Arm, Shoulder and Hand questionnaire (DASH), and Functional Assessment of Cancer Therapy for breast cancer QOL questionnaire (FACTB+4). The vertical perometer (400T) measured percentage upper limb volume difference (%LVD), with 10% or greater difference diagnosed as lymphedema. Of 617 participants (mean age 62.3y, SD 10.0; mean time since treatment 63.0 months, SD 46.6), sufficient questionnaire data were available for 613 and perometry data for 417. Using the MST, 21.9% self-reported impaired ULF, 19.8% lymphedema, and 9.2% both. Based on %LVD, 26.5% had lymphedema. Histogram analysis for individuals in the first eight twelve-month intervals after treatment found impaired ULF prevalence peaked at three to five years and lymphedema at three years. Significantly worse function (DASH) and QOL (FACT B+4) resulted for those with morbidity (p
      PubDate: Sep 2013
  • Screening of Ameloblastoma Cases in Ibadan for HPV and EBV Genes

    • Abstract: Publication date:  Sep 2013
      Source:Cancer and Oncology Research  Volume  1  Number  2  Olugbenga Samson Onile Onyegbula  Kenneth Okoje  Victoria and Anumudu  Chiaka This study investigated the presence or absence of Epstein-Barr virus and Human papilloma virus genes in ameloblastoma, in order to elucidate the genetic origin of this tumour. Methods and Material: 89 archived formalin-fixed paraffin-embedded specimens of ameloblastoma from the year 2000-2010 were genotyped by polymerase chain reaction for Epstein-Barr virus and Human papilloma virus genes Results: None of the 89 ameloblastoma cases used for this study tested positive for Epstein-Barr virus and Human papilloma virus genes. Conclusions: This study suggested that Epstein-Barr virus and Human papilloma virus genes may likely not be involved in the aetiopathogenesis of ameloblastoma in Ibadan environment. Key Messages: Studies have suggested that HPV might be implicated in the pathogenesis of ameloblastoma. In this study none of the extracted DNA samples from the 89 ameloblastoma cases amplified for HPV primer in the PCR, as this may possibly clear the role of this virus in the etiopathogenesis of ameloblastoma or may indicate need for other primers. Further investigation should be done to clarify EBV role in ameloblastoma.
      PubDate: Sep 2013
  • Safe Cancer Screening for Patients after Lumpectomy, Survivors, and
           Healthy Subjects

    • Abstract: Publication date:  Sep 2013
      Source:Cancer and Oncology Research  Volume  1  Number  2  Emad Y. Moawad The purpose of this study is to establish an inexpensive test for cancer screening with safe clinical staging suitable to undergo anytime without risks or restrictions to the entire population, contributes to treatment management, and helps to administer the appropriate low-waste dose for all cancer therapies. Regarding cancer as a matter of energy balances; the mathematical model of the Emad Value Test (EVT) monitors the Extra Body Growth Energy (EB EG) of subject's whole body along dietary treatment which permits all the aberrant activation of body cells that lead to cancer development and simply describes the patient cancer stage. According to work-energy principle, the initial energy of the low-waste dose (E0.Does) would be equivalent to that of the (EB EG) at the end of the EVT period. i.e. (EB EG) = (E0.Does). Simulations of the presented model showed that Energy Intake (EI), Total Energy Expenditure (TEE), and the Accumulated Extra Body Growth Energy (AEB EG), were always balanced with their subsequent Energy Stored (Estored) or Energy Loss (ELoss) by the body along the diet period according to law of conservation of energy to confirm and provide a clear-cut criterion for accepting the EVT hypothesis for the relationship between the Estored or ELoss, the difference and the (AEB EG) as follows: Estored= (EI –TEE) – (AEB EG) or ELoss= (TEE – EI) + (AEB EG) Validity of EVT results as a diagnostic tool recommends EVT to be considered as more reliable test with promising efficacy and low cost to obtain a more accurate assessment as to whether cancer is present in healthy subjects, besides to staging, restaging cancer for patients and screening survivors as well. EVT provides also the possibility to investigate all effects of the human-caused background radiation, and all cancer causes.
      PubDate: Sep 2013
  • Breast Tumor Localization Using Simultaneous Perturbation
           Stochastic-Neural Algorithm

    • Abstract: Publication date:  Nov 2013
      Source:Cancer and Oncology Research  Volume  1  Number  3  Ahmad AbdulSadda   Many impalpable or occult breast cancers cannot be localized using imaging techniques like mammography and ultrasound. An accurate localization of the tumor is, however, essential to guide the surgeon to the lesion, and ensure its correct and adequate removal with satisfactory excision margins. Current breast tumor localization techniques are invasive and often result in a cosmetic disfigurement. In this paper, we use the ultrawide band radar-based microwave breast imaging technique to non-invasively localize (impalpable) tumors in the breast. We consider four clinically important lesion features: location, size, depth and spatial orientation within the breast. A comparison of the energy of the received signal from healthy and cancerous breasts exhibits some remarkable differences in some frequency bands. We, therefore, use the energy spectrum of the receiving antenna signal decomposed by wavelet transform as the input to a Simultaneous Perturbation Neural Network (SPNN) classifier. Furthermore, we determine the optimum structure and gains of the SPNN, in terms of optimum initial weights and optimum number of nodes in the hidden layer. We use CST Microwave Studio to simulate a data set of 1024 cancer cases with various tumor location, size, depth and direction inside the breast. Our results show that the proposed algorithm gives accurate localization of the breast lesion, and possesses a high sensitivity to small tumor sizes. Additionally, it can accurately detect and classify multiple tumors with short learning and testing time.
      PubDate: Nov 2013
  • Pathologic Cancer Staging by Measuring Cell Growth Energy

    • Abstract: Publication date:  Nov 2013
      Source:Cancer and Oncology Research  Volume  1  Number  3  Emad Y. Moawad   The aim of this research is to establish a pathologic cancer staging by measuring Cell Growth Energy (CGE) contributes to treatment management and helps to administer the appropriate low-waste dose for all cancer therapies. Regarding cancer as a cell cycle disruption disease; Nitrogen-containing bisphosphonates (NBP) Alendronate (ALN) of different concentrations were added to samples of Normal Human Epidermal Keratinocytes (NHEKs) (20,000Cell /sample) to inhibit their growth rate to model cancer effects on normal cells, [14C] thymidine was added at 0.5 μCi/ml to each of control sample and those of cell cycle arrest (with NBPs) to monitor the Cell Growth Energy (CGE) which expresses all aberrant activations of cell that lead to cancer development and simply describes the cancer stage of the cell. Radioactivity incorporated (% of control) at 37℃ was determined as a measure of cell rate of growth at 24-h intervals for 3 days using a Top Count NTX micro plate scintillation counter. NHEKs rate of growth for sample with NBP of concentration 10 μM ALN was the closest to that of induced carcinomas, equivalent to 87% of that of the normal counterpart as measured by [14C ] thymidine incorporation (p
      PubDate: Nov 2013
  • Thymic Carcinoid: A Rare Case Presentation

    • Abstract: Publication date:  Jul 2013
      Source:Cancer and Oncology Research  Volume  1  Number  1  Ashfaq Ul Hassan Carcinoid tumors are not a common entity in thorax. The most common sites include the abdominal sites like the Appendix and the Ileum . The carcinoids in the thorax are seen rarely and that to thymus the carcinoids are all together rare. Usually carcinoids tend to be Chromaffin positive histologically and secrete a largr number of chemicals. They belong to the APUD system(Amine Precursor Uptake and decarboxylation system). Thymic carcinoid is a distinct entity which is very rare. It is a slow growing but potentially malignant tumor. We present a rare case of thymic carcinoid in a 16 year old male. Fortunately the disease was confined to Thymus and there was no metastatic spread to other organs. Cytological examination of samples obtained by ultrasound guided fine needle aspiration provided the diagnosis in the patient.
      PubDate: Jul 2013
  • Safe Doses and Cancer Treatment Evaluation

    • Abstract: Publication date:  Jul 2013
      Source:Cancer and Oncology Research  Volume  1  Number  1  Emad Y. Moawad The aim of this research is to check the efficacy of radiotherapy after execution that helps in preserving patients' rights against the randomized dose that settled statistically and assessed in standard models ignoring patient-specific factors. Based on studying a dose–response relationship, a mathematical model is presented describes the initial tumor energy (E0Tumor) prior therapy after treatment execution -even if it was not predetermined- by monitoring the tumor response along the treatment phases and compared to the applied dose energy (E0Dose). Our model allows mechanic risk predictions to be made at high radiotherapeutic doses as well as at low doses, besides to the second cancer risk prevention. Thus, the administered dose errors could be determined and consequently preserving patients' rights to evaluate the cancer treatment through the provided mathematical model. Reasons of tumor regrowth are either underestimation or overestimation of the administered dose; the safe dose of the successful treatment occurs only in the case of: E0Dose = E0Tumor, where tumor regrowth energy in such a case would be vanished. Dose assessment by ignoring patient-specific factors and using standard models is responsible for wide range of doses that lead to tumor regrowth and second cancer risks. Current approach suggests settling down a new protocol for the proper ranges of radionuclide doses based on a personalized staging system.
      PubDate: Jul 2013
  • Utilizing SPR as a Novel Technique to Measure Cell Aggregation for
           Ketamine Treated Brain Gliomas

    • Abstract: Publication date:  Jul 2013
      Source:Cancer and Oncology Research  Volume  1  Number  1  N. Ya. Gridina This work is devoted to a new approach to use of the inhibitor of glutamate-ionotropic NMDA-receptor-ketamine in treatment of rat malignant gliomas. Optimal ketamine concentrations for inhibition of tumor-associated inflammation in gliomas was found through measurement of blood cells aggregation in vitro in patients with gliomas. For the first time, the method of surface plasmon resonance was used to determine the degree of blood cell aggregation as the II phase of inflammation. Experiments for measure of ketamine antitumor activity were performed using the high-invasive and malignant strain of the rat glioma 101.8. The correlation between antitumor activity and blood cells aggregation was found. Unlike highly toxic preparations administered during human gliomas chemotherapies, low doses of ketamine is nontoxic, efficacious and it does not produce side effects.
      PubDate: Jul 2013
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
Home (Search)
Subjects A-Z
Publishers A-Z
Your IP address:
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2016